AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis
NCT ID: NCT02161146
Last Updated: 2019-04-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
240 participants
INTERVENTIONAL
2014-06-04
2014-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
AGN-229666 for the Treatment of Allergic Conjunctivitis
NCT01754766
AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis
NCT02082262
Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients
NCT01109485
An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis
NCT01037179
Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
NCT01363700
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AGN-229666
One drop of AGN-229666 in each eye on Days 1 and 15.
AGN-229666
One drop of AGN-229666 in the eye on Days 1 and 15.
Vehicle
One drop of Vehicle to AGN-229666 in each eye on Days 1 and 15.
Vehicle to AGN-229666
One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15.
Olopatadine
One drop of olopatadine in each eye on Days 1 and 15.
Olopatadine
One drop of olopatadine in the eye on Days 1 and 15.
AGN-229666/Olopatadine
One drop of AGN-229666 in one eye and one drop of olopatadine in the other eye on Days 1 and 15.
AGN-229666
One drop of AGN-229666 in the eye on Days 1 and 15.
Olopatadine
One drop of olopatadine in the eye on Days 1 and 15.
AGN-229666/Vehicle
One drop of AGN-229666 in one eye and one drop of Vehicle to AGN-229666 in the other eye on Days 1 and 15.
AGN-229666
One drop of AGN-229666 in the eye on Days 1 and 15.
Vehicle to AGN-229666
One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AGN-229666
One drop of AGN-229666 in the eye on Days 1 and 15.
Vehicle to AGN-229666
One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15.
Olopatadine
One drop of olopatadine in the eye on Days 1 and 15.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* History of an eye herpetic infection.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tokyo, , Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Nakatani H, Gomes P, Bradford R, Guo Q, Safyan E, Hollander DA. Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized Study. Ocul Immunol Inflamm. 2019;27(4):622-631. doi: 10.1080/09273948.2018.1432764. Epub 2018 Mar 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
229666-006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.